HCMV is remarkably successful as demonstrated by (i) its ubiquity within the human population, (ii) periodic shedding of infectious virus in the presence of host immune responses, and (iii)its ability to infect previously immune hosts. These facts are not surprising considering the evolutionary genealogy of HCMV and the other members of Herpesviridae. Since viruses are obligate intracellular pathogens, the herpesviruses must have evolved comlex mechanisms to maintain themselves in host populations in the face of innate and adaptive barriers to viral replication. HCMV encodes a highly choreographed strategy of attenuating host immune responses to overcome the stringent requirements imposed by the viral life cycle. For any HCMV vaccine to be effective, it must elicit a level of protective immunity that is greater than that generated following primary infection with wild-type virus by impeding the virus'ability to manipulate host immune responses. We previously proposed that HCMV immunomodulatory proteins should be included as vaccine targets since these proteins mediate the establishment of persistence. Results during the funding period demonstrate that cmvlL-10 treatment induces changes in dendritic cells (DC) functions in vitro. Inoculation of macaques with an IL-10-deleted variant of rhesus CMV (RhCMV) results in marked changes in the innate and adaptive immune responses. The results support the interpretation that cmvll_-10acts as an anti- inflammatory cytokine that skews host immunity at the earliest stage of viral infection. The hypothesis is presented that HCMV stimulates immune responses that, while protecting against disease, are insufficient to prevent persistence or protect against reinfection due to the actions of cmvll_-10. The hypothesis will be tested in rhesus macaques through the following Aims. (1) Immunization and challenge of macaques by a cmvlL-10 DMA priming/protein boost strategy followed by wild-type RhCMV challenge. (2) Immunization of macaques with RhCMVAILIO followed by RhCMV challenge. (3) Double immunization strategy of cmvlL-10 DMA priming/protein boosting and inoculation with RhCMVAILIO,followed by RhCMV challenge. (4) Site- directed mutation of the cmvll_-10 gene and protein. It is reasonable to expect that a successful HCMV vaccine strategy has to the match the complexity of HCMV natural history. This application seeks to demonstrate that a vaccine directed against cmvlL-10 should be included as one of the components.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI049342-09
Application #
7738911
Study Section
Special Emphasis Panel (ZRG1-VMD (01))
Program Officer
Beisel, Christopher E
Project Start
2001-04-01
Project End
2011-11-30
Budget Start
2009-12-01
Budget End
2011-11-30
Support Year
9
Fiscal Year
2010
Total Cost
$400,912
Indirect Cost
Name
University of California Davis
Department
Pathology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Eberhardt, Meghan K; Deshpande, Ashlesha; Fike, Joseph et al. (2016) Exploitation of Interleukin-10 (IL-10) Signaling Pathways: Alternate Roles of Viral and Cellular IL-10 in Rhesus Cytomegalovirus Infection. J Virol 90:9920-9930
Yue, Yujuan; Kaur, Amitinder; Lilja, Anders et al. (2016) The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains. J Gen Virol 97:1426-38
Kuruganti, Srilalitha; Miersch, Shane; Deshpande, Ashlesha et al. (2016) Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes. J Biol Chem 291:447-61
Zhang, Mingce; Bracaglia, Claudia; Prencipe, Giusi et al. (2016) A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. J Immunol 196:2492-503
Khass, Mohamed; Blackburn, Tessa; Burrows, Peter D et al. (2016) VpreB serves as an invariant surrogate antigen for selecting immunoglobulin antigen-binding sites. Sci Immunol 1:
Barry, Peter A (2015) Exploiting viral natural history for vaccine development. Med Microbiol Immunol 204:255-62
Eberhardt, Meghan K; Barry, Peter A (2014) Pathogen manipulation of cIL-10 signaling pathways: opportunities for vaccine development? Curr Top Microbiol Immunol 380:93-128
Deere, Jesse D; Barry, Peter A (2014) Using the nonhuman primate model of HCMV to guide vaccine development. Viruses 6:1483-501
Assaf, Basel T; Mansfield, Keith G; Strelow, Lisa et al. (2014) Limited dissemination and shedding of the UL128 complex-intact, UL/b'-defective rhesus cytomegalovirus strain 180.92. J Virol 88:9310-20
Kuruganti, Srilalitha; Accavitti-Loper, Mary Ann; Walter, Mark R (2014) Production and characterization of thirteen human type-I interferon-? subtypes. Protein Expr Purif 103:75-83

Showing the most recent 10 out of 29 publications